Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

100.58 -1.47 (-1.45%)
Streaming Delayed Price Updated: 10:17 AM EDT, Apr 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Jazz Pharmaceuticals PLC (JAZZ) Q3 2021 Earnings Call Transcript
JAZZ earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Jazz Pharmaceuticals Reports Q3 Financial Results, Raises Full-Year Earnings Guidance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharma... 
Via Benzinga
Jazz Pharmaceuticals: Q3 Earnings Insights
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus SAB Spikes On Analyst Action SAB Biotherapeutics, Inc. (NASDAQ: SABS) shares... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures
Lexaria Bioscience Corp (NASDAQ: LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure... 
Via Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
2 Top Growth Stocks to Buy Heading Into November
There's plenty of growth on the horizon for these stocks, which are trading near their lows for the year. 
Via The Motley Fool
Jim Cramer Considers nCino As Winner, Prefers This Stock Over Perficient
On CNBC’s "Mad Money ... 
Via Benzinga
Leading the Charge to Develop the First Orexin-Targeted Therapy to Address Narcolepsy at its Root Cause
Photo by MART PRODUCTION from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals
The Securities and Exchange Commission has charged a former Goldman Sachs (NYSE: GS) compliance analyst with using confidential information to generate over $... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
Needham Initiates Coverage With Buy For This Narcolepsy Player
Needham 
Via Benzinga
September Sell-Off: 3 Dirt Cheap Growth Stocks to Buy
Get these stocks while they're near their 52-week lows. 
Via The Motley Fool
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021
Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ: 
Via Benzinga
Sales Of Three Major Pharmaceutical Cannabis Products Set To Reach €1.8 Billion By 2025
By Prohibition Partners Combined sales of the three most lucrative cannabis pharmaceuticals products - Epidiolex®, D... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
3 Biotech Stocks That Are Too Cheap to Ignore
You'll definitely want to check out these biotech bargains. 
Via The Motley Fool
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... 
Via Benzinga
Canada Approves Jazz Pharma's Excessive Daytime Sleepiness Med
Health Canada has approved Jazz Pharmaceuticals plc's (NASDAQ: JAZZ) Sunosi (solriamfetol) for excessive daytime sleepiness (EDS) associated with narcolepsy or... 
Via Benzinga
Got $4,000? Buy These 2 Cannabis-Focused Biotech Stocks
Neither of them needs to sell marijuana to consumers to succeed. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
10 Small And Mid-Cap Growth Stocks To Buy Today
If you are looking for long-term growth, you will most likely find it in small and mid-cap stocks because they have the room to grow. The bigger a company gets, the more difficult it is to achieve... 
Via Talk Markets
This Cannabis Stock Is Full of Potential and Hasn't Been This Cheap in Months
Investors have been selling off the stock since the company released its earnings report earlier this month. 
Via The Motley Fool
Topics Cannabis
Exposures Cannabis
10 Biggest Price Target Changes For Monday
UBS boosted the price target on Seagate Technology Holdings plc (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small- and mid-cap companies among... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow
Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.